NCT07053800View on ClinicalTrials.gov

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2030

Conditions

Lupus Nephritis

Interventions

BIOLOGICAL

Obecabtagene autoleucel

Obecabtagene autoleucel (obe-cel) given as a single infusion

Sponsors

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

Autolus Limited

INDUSTRY